HeartBeam, Inc.

BEAT Healthcare Health Information Services

In the quarter to June 2026, EPS grew 33.3% and free cash flow fell 1.24%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.44 0.01 +2.33%
Market cap
$24.3M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a

Insider Decisions trades per month

Total buys 0.95
Total sells 1.08
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — 9 — — — — — —
Sell — 2 — — — — — — — — — —
Insider Ownership 12.33%

Capital & Financial Ratios $m

Market Cap 24.32
Revenue —
Net Income (20.30)
Free Cash Flow (14.01)
Net Debt (8.72)
Current Ratio 3.66 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E —
P/S ratio 0.00
P/B ratio 2.84
Past 5Y EPS Growth —
This Y EPS Growth 38.17% (at or above 15%: strong)
Next Y EPS Growth 25.22% (at or above 15%: strong)
Next Y revenue growth —
Next 5Y EPS Growth 28.15% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 32.34%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2020 Powerpack
2019 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 16 2 4 9
Receivables — — — —
Inventory — — 0 0
Other — — — —
17 3 5 9
2023 2024 2025 Q'26
Payables 1 1 1 1
ST’ Debt — — — —
Other — — — —
1 2 3 2

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 3.12%

Revenue $m

Year
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (3) — — —
’25 (4) (3) (3) (3) (14)
’24 (3) (4) (3) (4) (14)
’23 (3) (4) (2) (3) (12)
’22 (2) (2) (3) (3) (10)
’21 0 0 0 (2) (3)
’20 0 0 0 0 (1)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (4) — — —
’25 (4) (4) (3) (3) (15)
’24 (4) (4) (3) (4) (15)
’23 (3) (4) (2) (3) (12)
’22 (2) (2) (3) (3) (10)
’21 0 0 0 (2) (3)
’20 0 0 0 0 (1)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.12) (0.10) — — —
’25 (0.18) (0.15) (0.15) (0.14) (0.62)
’24 (0.17) (0.19) (0.19) (0.18) (0.73)
’23 (0.50) (0.16) (0.13) (0.13) (0.72)
’22 (0.27) (0.43) (0.44) (0.45) (1.59)
’21 (0.06) (0.26) (0.32) (0.40) (1.03)
’20 (0.02) (0.03) (0.09) — (0.29)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.7
1Buy 2 3Hold 4 5Sell

Ten years at a glance

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 2.75 1.12 1.06 1.35 0.54

Analyst estimates 2026–2028

Powerpack
High — — — — — 5.47 6.74 5.06 3.48 4.00
People
People Employees — — — — — — 15 15 21 16
Revenue/emp, $m — — — — — — 0.00 0.00 0.00 0.00
Income, $m
Income, $m Revenue — — — — — — — — — —
Gross margin, % — — — — — — — — — —
EBT — — — (1) (1) (4) (13) (15) (19) (21)
EBT margin, % — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net income — 0 — (1) (1) (4) (13) (15) (19) (21)
Depreciation — — — 0 0 2 — — 0 0
Per share, $
Per share, $ Revenue — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings — — — (0.16) (0.29) (1.03) (1.59) (0.72) (0.73) (0.62)
Cash flow — — — (0.06) (0.16) (0.75) (1.22) (0.59) (0.54) (0.41)
Capex — — — 0.00 0.00 0.00 0.00 (0.01) (0.01) (0.02)
Free cash flow — — — (0.06) (0.16) (0.75) (1.22) (0.61) (0.55) (0.43)
Book value — — — (1.09) (1.31) 3.13 0.29 0.78 0.06 0.08
Shares, m — — — 3 4 4 8 20 27 34
Valuation, ×
Valuation, × P/E — — — — — — — — — —
P/S — — — — — — — — — —
P/B — — — — — — — — — —
EV/Sales — — — — — — — — — —
EV/FCF — — — — — — — — — —
Cash, $m
Cash, $m Operating cash flow — — — 0 (1) (3) (10) (12) (14) (14)
Capex — — — — — — — 0 0 (1)
Free cash flow — — — 0 (1) (3) (10) (12) (15) (15)
Balance, $m
Balance, $m Working capital — — — 0 (5) 13 2 16 1 1
Total debt — — — 3 4 — — — — —
Net debt — — — 3 0 (13) (4) (16) (2) (4)
Shareholders’ equity — — — (4) (5) 13 2 16 2 3
Returns, %
Returns, % ROA — — — (15,314.29) (3,682.76) (63.04) (143.73) (138.30) (190.60) (460.91)
ROIC — — — 0.00 0.00 (655.10) 0.00 0.00 0.00 0.00
ROE — — — 12.59 25.09 (102.68) (164.24) (159.89) (221.11) (987.32)
Negative figures in brackets.

All 10 years →

Charts ten years each

HeartBeam, Inc. vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CCLD CareCloud, Inc. $82.0M 26.4× 12.5× +16.45% (above 0%: growing) n/m +6.15% (above 0%: growing) 45.24% 5.84% Compare
DRIO DarioHealth Corp. $50.3M — (loss-making) — (loss-making) −3.58% (below 0%: shrinking) n/m −0.74% (below 0%: shrinking) 61.66% (125.15%) Compare
ONMD OneMedNet Corporation $28.6M — (loss-making) — +88.39% (above 0%: growing) n/m +14.05% (above 0%: growing) (193.49%) (774.32%) Compare
BEAT HeartBeam, Inc. $24.3M — (loss-making) — — n/m −1.24% (below 0%: shrinking) — 0.00%
RNLXY Renalytix plc - Sponsored ADR $17.2M — (loss-making) — +13.73% (above 0%: growing) n/m +17.96% (above 0%: growing) 19.16% (783.91%) Compare
BFRG Bullfrog AI Holdings Inc. $9.9M — (loss-making) — +2,054.00% (above 0%: growing) n/m −5.67% (below 0%: shrinking) 49.63% (658.82%) Compare
ETAOF ETAO International Co., Ltd. $9.8M — (loss-making) — — n/m +37,595.70% (above 0%: growing) — 0.00% Compare
HCTI Healthcare Triangle, Inc. $7.4M 0.0× — (loss-making) +158.38% (above 0%: growing) n/m +67.48% (above 0%: growing) 22.48% (44.28%) Compare
MGRX Mangoceuticals, Inc. $7.1M — (loss-making) — −59.07% (below 0%: shrinking) n/m +79.27% (above 0%: growing) 64.24% (1,501.45%) Compare
Median of peers $13.6M — — +16.45% — +16.01% 45.24% (391.98%)

All 51 Health Information Services stocks →

HeartBeam, Inc. (BEAT) key facts

  • HeartBeam, Inc. (BEAT) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, BEAT traded at $0.44, a market capitalization of $24.3 million.
  • Return on equity was −987.3% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.

HeartBeam, Inc. (BEAT) Latest News

No news at this impact. Lower the threshold for more.

stockrow.com/BEAT · For information only; not investment advice. · © 2026 stockrow.com